

# AUTOVACUNAS BACTERIANAS

De la uretritis a la bartolinitis .....

Dra. Presentación García  
Dra. Esperanza Gadea  
Dra. Francisca Guirao  
Dra. Cristina Montoya  
Dra. Pilar Rodríguez




Área IX Hospital de Cieza Lorenzo Guirao







AUTOVACUNA  
ANTIBACTERIANA

Células Dendríticas



Ig A de mucosas




Mucosa

MALT

Submucosa




Células presentadoras de Antígenos



# ITUS POSTCOITALES

Colonización de la uretra anormal



# AUTOVACUNA ANTIBACTERIANA



76 Autovacunas bacterianas  
2019-2024


# 76 AUTOVACUNAS BACTERIANAS 2019-2024

Cistitis 40%

Uretritis 30%

Vaginosis/Candidiasis 25%

Bartolinitis 5%



CISTITIS 40% AUTOVACUNAS

CISTITIS 56%

Monobacterianas: E Coli./ Enterococcus Faecalis/  
Kbsiella/ Proteus 76%

Polimicrobiana: E Coli+Enterococcus.F+  
Candidas 24%

18% Cándidas implicadas en la infección

URETRITIS 44%


MONOBACTERIANA:

E.COLI/ENTEROCOCO FAECALIS/  
MORGANELLA 56%

POLIMICROBIANA:

ECOLI+ENTEROCOCO+CANDIDAS 43%

18% Cándidas implicadas en la infección



VAGINOSIS /CANDIDIASIS 30%  
AUTOVACUNAS

Monobacterianas

56% Cándidas/Ecoli/ Enterococo F


Polimicrobianas 44%:

Cándidas+ Ecoli + Estafilococo+Enterococo F

50% Candida Albicans  
50% Cándida SP

Monobacteriana E.Coli 80%

BARTOLINITIS RECIDIVANTES  
AGUDAS AUTOVACUNAS 7%



Mal Control Precisa tratamientos durante su uso:

Cistitis 29%

Uretritis 13%

Vaginosis 56%

Cándidas 33%

NO PRECISAN TRATAMIENTOS  
DURANTE LOS 6 MESES DE  
AUTOVACUNA

Cistitis 71%

Uretritis 86%

Vaginosis 42%

Candidiasis 66%

Bartolinitis 75%

## CISTITIS AUTOVACUNAS

57% recidiva antes de 2 años

23% recidiva a los 3 meses

15% recidiva a los 6 meses

23% recidiva 1 año

38% recidiva a los 2 años

43% no recidiva


# RECIDIVAS URETRITIS

Recidiva 61%

43% al año

57% a los dos años

Sin recidiva 39%



# AUTOVACUNA ANTIBACTERIANA



Tiempo de fabricación 6 semanas

Meses de tratamiento	
3 meses	21 pacientes
6 meses	40 pacientes
9 meses	5 pacientes
Mas de 12meses	11 pacientes



**NIH Public Access**  
**Author Manuscript**  
The Authorial Manuscript is published in PMC on 12 February 2014  
 Published in final edited form as:  
*Curr Infect Dis Rep* 2011 February ; 13(1): 102-107. doi:10.1007/s11908-010-0143-y

**Prospects for Development of a Vaccine to Prevent and Control Vaginal Candidiasis**

Translating to MICROBIOLOGY **REVIEW ARTICLE**  
doi:10.1007/s11908-010-0143-y

**New approaches in the development of a vaccine for mucosal candidiasis: progress and challenges**

**Anna Vecchiarelli<sup>1</sup>, Eva Pericolini, Elena Gabrielli and Donatella Pietrella**  
Microbiology Section, Department of Experimental Medicine and Biomedical Sciences, University of Perugia, Perugia, Italy

Estudio piloto sobre la prevención de las infecciones urinarias recurrentes mediante el uso de extractos bacterianos



Hospital General Universitario de Castellón  
 Facultad de Medicina en Castellón, de la Universidad de Castilla-La Mancha

**European Urology**  
European Urology 47 (2005) 542-548

**A Long-Term, Multicenter, Double-Blind Study of an *Escherichia Coli* Extract (OM-89) in Female Patients with Recurrent Urinary Tract Infections**

Hartwig W. Bauer<sup>a</sup>, Schanaz Alloussi<sup>b</sup>, Günther Egger<sup>c</sup>, Hans-Martin Blümlein<sup>d</sup>, Gabriel Cozma<sup>e,f</sup>, Claude C. Schulman<sup>g</sup>  
 on behalf of the Multicenter UTI Study Group<sup>1</sup>

**RECURRENT URINARY TRACT INFECTIONS: CAN IMMUNOACTIVE PROPHYLAXIS IMPROVE DISEASE MANAGEMENT IN HEALTHY WOMEN?**

Narrative Summary of Selected Presentations given at the OM Pharma/Vifor Pharma URO-VAXOM<sup>®</sup> Summit, held in Buenos Aires, Argentina, on 26<sup>th</sup>-27<sup>th</sup> April 2014

Björn Wullt,<sup>1</sup> Florian ME Wagenlehner,<sup>2</sup> Peter Tenke<sup>1</sup>

Available online at [www.sciencedirect.com](http://www.sciencedirect.com)  
**ScienceDirect**  
Procedia in Vaccinology 9 (2015) 35 – 37

**Procedia in Vaccinology**  
www.elsevier.com/locate/procedia

8th Vaccine & ISV Congress, Philadelphia, USA, 2015

**Use of yeast lysate in women with recurrent vulvovaginal candidiasis.**

Vrzal, V.<sup>a</sup>, Bittner, L.<sup>a</sup>, Nepereny, J.<sup>a</sup>  
<sup>a</sup> Biocena, s. r. o., Komenského 152, 602 00 Brno, Czech Republic

**Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet].**

Database of Abstracts of Reviews of Effects (DARE)  
 Quality-assessed Reviews

[Show details](#)

**Immunoactive prophylaxis of recurrent urinary tract infections: a meta-analysis**

KG Naber, YH Cho, T Matsumoto, and AJ Schaeffer.

Review published: 2009.

**American Journal of Life Sciences**  
 2014; 2(6-3): 13-17  
 Published online November 23, 2014 (<http://www.sciencepublishinggroup.com/j/ajls>)  
 doi: 10.11648/j.ajls.a.2014020603.13  
 ISSN: 2328-5702 (Print); ISSN: 2328-5737 (Online)

**Autovaccines for chronic urinary tract infections; ten years follow-up experience**

Gallego-Vilar Daniel<sup>1</sup>, Sanchis-Verdu Laura<sup>2</sup>, Beltran Persiva Jose<sup>1</sup>, Cuñat-Albert Enrique<sup>2</sup>, Cervello-Grima Enrique<sup>1</sup>, Gallego-Gomez Juan<sup>2</sup>, Perez-Mestre Mateo<sup>3</sup>

Available online at [www.elsevier.com](http://www.elsevier.com)  
**ScienceDirect**  
International Journal of Antimicrobial Agents 39 (2002) 431–436

**Antimicrobial Agents**  
www.elsevier.com

**Prevention of recurrent urinary tract infections with immuno-active *E. coli* fractions: a meta-analysis of five placebo-controlled double-blind studies**

Hartwig Wilhelm Bauer<sup>a,\*</sup>, Volker W. Rahlfs<sup>b</sup>, Pierre A. Lauener<sup>c</sup>, Gabriela S.S. Bleßmann<sup>d</sup>

BJU Int 2022; 130: Supplement 3: 11–22 doi:10.1111/bju.15756

**Review**

**Guideline of guidelines: management of recurrent urinary tract infections in women**

Michael Kwok<sup>1,2,3</sup>, Stephen McGeorge<sup>1,2</sup>, Johanna Mayer-Coverdale<sup>4</sup>, Bianca Graves<sup>4</sup>, David L. Paterson<sup>5,6</sup>, Patrick N.A. Harris<sup>6,7</sup>, Rachel Esler<sup>1,2</sup>, Caroline Dowling<sup>8</sup>, Sumudu Britton<sup>6,9</sup> and Matthew J. Roberts<sup>1,3,6</sup>

<sup>1</sup>Department of Urology, Royal Brisbane and Women's Hospital, <sup>2</sup>Faculty of Medicine, University of Queensland, <sup>3</sup>Herston ID Institute (HEIDI), <sup>4</sup>Department of Infectious Diseases, Royal Brisbane and Women's Hospital, <sup>5</sup>Faculty of Medicine, University of Queensland Centre for Clinical Research, <sup>6</sup>Central Laboratory, Pathology Queensland, Brisbane, <sup>7</sup>Department of Urology, Redcliffe Hospital, Redcliffe, <sup>8</sup>Infection and Inflammation Program, QIMR Berghofer Medical Research Institute, Herston, Qld and <sup>9</sup>Department of Urology, Eastern Health, Melbourne, Vic., Australia

RESUMEN DE COMUNICACIÓN

Título: **EMPLEO DE AUTOVACUNAS EN EL TRATAMIENTO DE LAS INFECCIONES DE REPETICIÓN DE TRACTO URINARIO.**

Autor/es: Daniel Gallego Vilar; Marta García Torrelles; David Martínez Ramos; Vicente Cabrera Chabrera; Vicente Francisco; Juan Gallego Gómez

Institución: Hospital general de Castellón

Texto: INTRODUCCIÓN: Presentar nuestra experiencia en el uso de autovacunas para el tratamiento de las ITUs de repetición refractarias al tratamiento antibiótico.

**A Long-Term, Multicenter, Double-Blind Study of an *Escherichia Coli* Extract (OM-89) in Female Patients with Recurrent Urinary Tract Infections**

Hartwig W. Bauer<sup>a</sup>, Schanaz Alloussi<sup>b</sup>, Günther Egger<sup>c</sup>

**Prevención de infecciones recurrentes del tracto urinario con immunoactivo**  
 Fracciones de *E. coli*: un metaanálisis de cinco dobles controlados con placebo  
 Estudios ciegos  
 Hartwig Wilhelm Bauer a,\* , Volker W. Rahlfs b, Pierre A. Gabriela Lauener c  
 S.S. Bleßmann d  
 A Maximilianstraße 31, 80539 München, Alemania  
 B idv-Datenanalyse und Versuchsplanung, Wessobrunner Straße 6, 82131 Gauting, München, Alemania  
 C Healthcare & Pharma Consulting SA, Genève  
 Ve, 8, av. Des Grandes-Communes, CH-1213 Petit-Lancy, Ginebra, Alemania  
 D Sanofi Winthrop GmbH, Augustenstraße 10, 80333 München, Alemania


**Actas Urológicas Españolas**  
 Volume 40, Issue 4, May 2016, Pages 201-208

Artículo de revisión

**Vacuna oral (OM-89) en la profilaxis de infección urinaria recurrente: una revisión sistemática realista con metaanálisis**  
 Oral vaccine (OM-89) in the recurrent urinary tract infection prophylaxis: a realistic systematic review with meta-analysis

K.A. Taha Neto<sup>a</sup>, L. Nogueira Castilho<sup>b</sup>, L.O. Reis<sup>c</sup>

**A Retrospective Study of Immunotherapy Treatment with Uro-Vaxom (OM-89®) for Prophylaxis of Recurrent Urinary Tract Infections**



## AUTOVACUNAS ANTIBACTERIANAS

Excelente control agudo de cistitis y uretritis mientras se administra al menos 6 meses (70-80%)

Menor eficacia en vaginosis/candidiasis




La administracion prolongada en casos severos mejora la eficacia




GRACIAS



presentacion garcia instituto IGEMA





## NINGUN EPISODIO POSTERIOR


CISTITIS 43%


URETRITIS 39%

VAGINOSIS 28%

CANDIDIASIS 33%

BARTOLINITIS 75%





ITUS DE REPETICION

MÁS DE 3 ANUALES O MÁS DE 2 EN 6 MESES

URETRITIS/ITUS POSTCOITALES